Abstract. Treatment with activated autologous lymphocytes (AALs) has demonstrated mixed results for cancer treatment. Preliminary results revealed that the proportion of cluster of differentiation (CD)8 + CD57 + T cells is significantly increased in AALs, indicating that they are able to determine treatment outcome. Therefore, the role of CD8 + CD57 + T cells in AAL efficacy was investigated. T lymphocytes were isolated from 35 patients with stage IV gastric carcinomas (17 men and 18 women; aged 41-84 years) receiving immunotherapy using AALs (IAAL). Using fluorescence activated cell sorting, CD8, CD27, CD57, and forkhead box protein 3 (FOXP3) expression was investigated on CD8 + T cell populations in CD8 + T cell differentiation prior to and following in vitro culture. The association between these populations and progression-free survival (PFS) was analyzed using Cox univariate, and multivariate analyses and Kaplan-Meier survival analysis. CD57 expression was negative in early-differentiated CD8 + T cells, which are the most mature effector (T MME ) cells, have been recognized as the most potent effector cells. They express high levels of granzyme B (GB) and perforin, and may induce effective cytotoxicity against tumor cells ( Fig. 1 
) (2-4). CD8
+ CTL differentiation is essential for maintaining a pool of mature CTLs in the blood (2-4). However, differentiation of early-CD8 + T cells toward the T MME phenotype is inhibited by transforming growth factor-β, interleukin (IL)-10, and programmed cell death protein-1 in patients with cancer, in whom the accumulation of incompletely differentiated early-and intermediate-CD8
+ T cells leads to uncontrolled progression of malignant cells (2) (3) (4) .
A previous study reported that patients with advanced gastric cancer with a high (>18%) CD57+ T cell percentage in the peripheral blood had a shorter survival time compared with those with a low percentage (<18%) (5) . In this study, it was demonstrated that a high CD57 + T cell percentage is an independent poor prognostic factor in patients with advanced gastric carcinomas (5 (13, 14) . Transient expression of FOXP3 during CD8 + T cell activation may be a mechanism for limiting excessive immune activation and damage at the site of inflammation (15, 16) . Since these reports indicated certain roles for FOXP3 in CD8 + T cell differentiation, the present study investigated the expression of FOXP3 in activated autologous lymphocytes (AALs).
As induction of T MME is the most important feature of immunotherapy using AALs (IAAL), the present study aimed to investigate the association between CD57-associated populations in the CD8 + T cell differentiation pathway (early-CD8 
Patients and methods
Patients. All participants provided written informed consent prior to enrollment in the present study. Patients with Stage IV gastric carcinomas diagnosed according to the unified TNM classification (17) and with a performance status (Eastern Cooperative Oncology Group Performance Status) between 0 and 2 were eligible for the present study. The study protocol was approved by the Institutional Review Board at each participating center, Tamana Regional Health Medical Center (Tamana, Japan) and Kumamoto University (Kumamoto, Japan). All methods and procedures associated with the present study were conducted in accordance with the Good Clinical Practice guidelines and accorded ethically with the principles of the Declaration of Helsinki and local laws.
A total of 35 patients receiving IAAL at the Tamana Regional Health Medical Center and Hakuzandori Clinic (Tokyo, Japan) between July 2013 and March 2015 were enrolled in the current study. The patients with stage IV gastric carcinoma (17 men and 18 women) ranged between 41 and 84 years in age (mean ± standard deviation, 59.4±11.0 years).
Sample collection and processing. Peripheral blood samples (50 ml) were collected from all eligible patients prior to and following IAAL; patient eligibility was determined by the presence of histologically and clinically diagnosed carcinoma. Mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation as follows: With a sterile pipette, the Ficoll-Hypaque solution was placed into a 50-ml conical centrifuge tube, using 2 ml of Ficoll-Hypaque/1 ml blood; anticoagulated blood was mixed with an equal volume of PBS; the diluted blood was slowly layered over the Ficoll-Hypaque solution by gently pipetting the diluted blood down the side of the tube containing the Ficoll-Hypaque; samples were centrifuged for 40 min at 400 x g (22˚C) with no brake; mononuclear cells, located at the interface between the plasma (upper layer) and the Ficoll-Hypaque (bottom) were carefully removed using a Pasteur pipette; the aspirated mononuclear cells were transferred to a 15-ml conical tube; mononuclear cells were cultured for 2 weeks with recombinant IL-2 (700 IU/ml; Shionogi & Co., Ltd., Osaka, Japan) and immobilized using anti-CD3 monoclonal antibody for 2 weeks at 37˚C (MAb) (cat. no. 12277, 5 µg/ml; Janssen-Kyowa; Johnson & Johnson, New Brunswick, NJ, USA). Sixteen-well cell cultures were performed for cells obtained from patients assigned to immunotherapy, preserving ~2x10 10 cells as the source for the second to the fifth infusions (18) ; however, cultures were discontinued for patients assigned to other treatments (18) . Briefly, mononuclear cells are separated from approximately 30 ml of peripheral blood and cultured with immobilized OKT3 and IL-2 for 3-5 days (RPMI-1640+9 Sin and RPMI-1640 HSR Sin, Lymphotec Inc). This step was designated the activation step. The activation step was followed by additional culture in a medium containing only IL-2 for 9-11 days in gas permeable bags (CP-4 and bagpack medium, Lymphotec Inc., Tokyo, Japan). This second step is designated the expansion step. Lymphocytes prior to and following the in vitro culture were phenotyped with MAbs against CD8 (RPA-T8; cat. no. 560917), CD27 (M-T271; cat. no. 557330), CD57 (NK-1; cat. no. 560844), and FOXP3 (259D/C7; cat. no. 560082) obtained from BD Biosciences (Franklin Lake, NJ, USA). These antibodies were diluted with IsoFlow (cat. no. 8599600) obtained from Beckman Coulter, Inc.
Samples were centrifuged at 652 x g at room temperature for 5 min to remove the supernatant, and then suspended in sheath solution. Antibodies (20 µl) were added to tubes in accordance with combinations shown in Table I . A total of 1 ml of each sample was added to each tube. Staining was performed by keeping on ice for tubes I to VI and at room temperature for tubes I' and VII, for ~20 min. To tubes I-VI, 2 ml sheath solution was added, and tubes were centrifuged at 652 x g at room temperature for 5 min. The supernatant was removed, and the pellet was suspended in sheath solution. Samples were evaluated using 3-color FACS analysis (Lymphotec, Inc., Tokyo, Japan) according to the manufacturers standard operating procedure.
The contents of tubes I' and VII were fixed by centrifuging at 250 x g for 10 min at room temperature with 2 ml of sheath solution. Buffer A (2 ml) was added and incubated in the dark at room temperature for 10 min. Tubes were centrifuged again at 500 x g for 10 min at room temperature, and the supernatant was removed.
The viability of the final cell products was determined using the dye exclusion test (trypan blue-exclusion test), and possible contamination by bacteria, fungi, and endotoxins was assessed twice (Ager medium method: Cell suspension (500 µl) was seeded on soybean-casein digest agar medium (cat. no. P94505R200; Nikken Biomedical Laboratory Inc., Kyoto, Japan,).
In order to maintain safety in the laboratory, a closed system was maintained for the first 7 days of culture. The growth of bacteria was investigated twice. First, 2 days before culture ended, and second 2 days post-culture. Only when no growth of bacteria was recognized were the cell products provided for patients.
Antibodies and fluorescence activated cell sorting (FACS).
The following reagents were used for FACS as described below: Anti-CD3-fluorescein isothiocyanate (FITC) (HIT3a; cat. no. 555339), anti-CD57-FITC (NK-1; cat. no. 555619), anti-CD27-phycoerythrin (PE) (M-T271; cat. no. 557330), anti-FOXP3-PE (259D/C7; cat. no. 560082), anti-CD56-PE (B159; cat. no. 561903), anti-CD57-PE (NK-1 cat. no. 560844), anti-CD4-PE-Cy7 (SK3; cat. no. 560909), and anti-CD8-PE-Cy7 (RPA-T8; cat. no. 560917) obtained from BD Biosciences. Cells were analyzed on a BD FACSCalibur 3A using BD FACS Express software (version 10.6.4; BD Biosciences). All antibodies with the exception of anti-FOXP3 were prediluted.
To each tube (1 ml) 2 ml sheath solution was added and tubes were centrifuged at 250 x g at room temperature for 10 min. The cell pellet was loosened by tapping the tubes, then 2 ml Buffer A was added and left to incubate in the dark at room temperature for 10 min. The tubes were centrifuged at 500 x g at room temperature for 10 min, the supernatant was removed, and the cell pellet loosened by tapping the tubes.
Buffer C (0.5 ml) was added to each tube, and incubated in the dark at room temperature for 30 min. Sheath solution (2 ml) was added and tubes were centrifuged at 500 x g for 10 min to remove the supernatant. An appropriate amount (300 µl) of sample was added to each tube. Staining was performed by keeping at room temperature for tubes I' and VII, for about 20 min.
FoxP3(PE) antibody was added and incubated in the dark at room temperature for 30 min. Sheath solution (2 ml) was added and samples were centrifuged at 500 x g for 10 min to remove the supernatant. The samples were once again suspended in sheath solution and centrifuged as aforementioned, then suspended in 300 µl sheath solution. Samples were evaluated using 3-color FACS analysis according to the manufacturers standard operating procedure Flow cytometric analysis. Two-color flow cytometry. Two-and three-color flow cytometric analyses were performed using the following MAbs: Leu-7-FITC (cat. no. 555619) and anti-CD3-PE for CD57 + T cells, anti-CD8-FITC and anti-CD57-PE for CD8 + CD57 + T cells, and anti-CD3-FITC and anti-CD56-PE for CD56
+ T cells (all BD Biosciences). Flow cytometric analysis was performed using a FACSCalibur flow cytometer (BD Biosciences). The proportions of CD56 + T cells and CD57 + T cells were expressed as a percentage of the total number of mononuclear cells.
Three-color flow cytometry.
A total of 1x10 6 cell/ml of sample was dispensed into each tube and incubated with the aforementioned MAbs for 20 min at 4˚C (tubes I-VI) for cell surface immunostaining or at room temperature for intracellular staining (tubes I' and VII). A total of 2 ml IsoFlow sheath liquid (Beckman Coulter Inc., Brea, CA, USA) was added to tubes I-IV, and the samples were centrifuged at 2,700 x g for Figure 1 . CD8 + T cell differentiation pathway. IL-2, interleukin-2; CD8, cluster of differentiation 8; GB, granzyme B; Perf, perforin; TCR, T cell receptor; Ag, antigen. + CD8 + T CELLS PREDICT POOR PROGNOSIS FOLLOWING IAAL 9532 5 min at room temperature. Thereafter, the supernatant was removed and replaced with sheath liquid. For tubes I' and VII, 2 ml sheath liquid was added, and the samples were centrifuged at 250 x g for 10 min at room temperature. The pellets were resuspended in 2 ml Buffer A (10-fold dilution of Human FOXP3 Buffer A from Human FoxP3 Buffer set with water; BD Biosciences) after removing the supernatant and maintaining for 10 min at room temperature. These samples were analyzed using a FACSCalibur 3A flow cytometer and FACS Express software 10.6.4 (both BD Biosciences).
Intracellular flow cytometry.
For intracellular staining, cells were fixed and permeabilized using the Human FoxP3 Buffer set, according to manufacturer's protocol. A total of 2 ml sheath liquid was added to each tube and centrifuged at 250 x g at room temperature for 10 min. The cell pellet was loosened by tapping the tubes, 2 ml Buffer A was added and the tubes were incubated in the dark at room temperature for 10 min. Tubes were centrifuged at 500 x g at room temperature for 10 min, the supernatant was removed and the cell pellet was loosened by tapping the tubes. Following the addition of 0.5 ml Buffer C (50-fold dilution of Human FOXP3 Buffer B with Buffer A) to each tube, the samples were incubated for 30 min at room temperature. Next, 2 ml sheath liquid was added, the samples were centrifuged at 500 x g for 10 min, and the supernatant was removed. PE-conjugated FOXP3 antibody (560082; BD Biosciences) was added and the tubes were incubated for 30 min at room temperature. Another 2 ml sheath liquid was added, the samples were centrifuged at 500 x g for 10 min, the supernatant was removed and the pellets were resuspended in 300 µl sheath liquid. These samples were analyzed as aforementioned.
Study endpoints and assessments. The primary endpoint of this study was progression-free survival (PFS). PFS was measured as the duration between the date of randomization and the date of first recurrence or mortality regardless of the cause. The secondary endpoints included overall survival (OS), and cancer-specific survival and safety. OS was measured as the duration between the date of randomization and the date of mortality from any cause; and cancer-specific survival was measured between the date of randomization and the date of mortality resulting from cancer. Tumor assessments were performed using dynamic computed tomography or magnetic resonance imaging every 3 months for 24 months, and every 3-6 months thereafter in the two groups. All scans at each site were reviewed by two independent, blinded radiologists, each with >5 years of experience. In cases of discordance, a third independent experienced radiologist reviewed the images to achieve a consensus. Adverse events (AEs) were classified and graded every 2 months according to the Common Terminology Criteria for Adverse Events (version 3.0; National Cancer Institute, Bethesda, MD, USA) (19) from the time that patient treatment was started until the end of the study or drop-out, continuing at least 30 days after the last dose of immunotherapy. Multiple events were counted once for each patient and the most severe event was summarized. The data collection cut-off date was November 29, 2015.
Statistical analysis. Data are expressed as the mean ± standard deviation. Comparison of non-normally distributed variables between groups was performed using the Mann-Whitney U-test. Comparison of categorical variables between two groups was performed using the χ 2 test. The probability of survival was estimated using the Kaplan-Meier method, and differences in survival rates were evaluated by log-rank test. Multivariate analysis of prognostic factors was conducted using the Cox regression model. All statistical analyses were conducted using SPSS version 13.0 for Windows (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Increased percentage of CD8
+ CD57 + T cells in AALs. The mean proportion of CD57 + T cells (51.7±2.6%), in particular the CD8 + CD57 + T cells (32.2±2.7%), was markedly increased following the incubation of lymphocytes obtained from the peripheral blood with anti-CD3 MAb and IL-2 when compared with the average proportions prior to culture (30.3±2.9 and 15±1.6%, respectively; Table II 
FOXP3
+ CD8 + T cells (Table II) . (Fig. 3) -FOXP3 + CD8 + T cells, whereas there was no significant difference between them prior to culture (Fig. 4A) . This decrease was more apparent when patients with high and low FOXP3 high CD27 high CD8 + CD57 -T cells were compared (Fig. 4B ).
Univariate and multivariate analysis of CD57-associated immune cells. Cox proportional-hazards regression analysis
Discussion
The An association between simultaneous expression of FOXP3 and CD27, and the poorest PFS of the four subgroups was also demonstrated in the present study, as CD27 expression was reported to discriminate regulatory from non-regulatory cells (27) . CD27, a member of the tumor necrosis factor receptor superfamily, serves as a co-stimulatory factor, and CD27 signaling leads either to improved T cell function or to T cell dysfunction, depending on the level, duration, and timing of CD27 ligand (CD70) expression (21, (28) (29) (30) . Consequently, CD70 expression is tightly regulated, and CD70 is only transiently expressed on activated T and B cells, and on subsets of professional antigen-presenting dendritic cells and natural killer cells (21) . By contrast, constitutive CD70 expression has been documented in various types of cancer, including brain tumors (20) , renal cell carcinomas (21) and certain lymphomas (31, 32) , and is often associated with FOXP3 + Treg formation (31, 32) . Thus, CD27 signaling mediated by constitutive CD70 expression is essential for the induction of FOXP3 + regulatory CD8 + T cells. Therefore, we hypothesize that CD27 is expressed on CD57 -FOXP3 + CD8 + T cells functioning as CD8
+ Tregs in the current study. Furthermore, the present study demonstrated that the proportion of CD57 -FOXP3 + CD8 + T cells was unchanged following culture, when compared with the pre-culture proportion, indicating that once CD57 -FOXP3 + CD8 + T cells (CD8 + Tregs) adopt a regulatory function, their phenotype cannot be changed despite an improvement in the microenvironment induced by IAAL. Previous reports demonstrated that an anti-human CD27 agonist MAb was shown to induce T cell activation and tumor immunity in human CD27-transgenic mice (33) through a combination of co-stimulation, and Treg-depleting activities (34) . These results indicated that a CD27-agonist MAb may deprive CD57 -FOXP3 + CD8 + T cells of their regulatory function as CD8 + Tregs and activate the co-stimulation signaling for CTLs to induce antitumor immunity. Thus, combinational immunotherapy using AALs and a CD27-agonist MAb may lead to more improved outcomes for IAAL.
In conclusion, the results of the present study demonstrated that terminal-CD8 + T cells are the T MME of IAAL, and that IAAL may promote CD8 + T cell differentiation to induce cytotoxic 
